Nant Capital is putting $22.6M into PDS Biotechnology, a clinical-stage biopharma developing T-cell stimulating immunotherapies aimed at cancer.
The company’s Versamune® platform is designed to train the body’s own immune system to attack tumors, a field that has drawn intense interest as oncology shifts toward more targeted, less toxic approaches. PDS Biotech, which is advancing candidates through clinical trials, will use the fresh capital to keep that work moving. The investment from Nant Capital-a firm known for backing ambitious healthcare bets-signals continued confidence in the platform’s potential, though the company has not detailed specific milestones tied to the round.


















